Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, single center and biomarker exploratory, phase II study.

ABSTRACT:

Background

Metastatic pancreatic cancer (mPC) has a dismal prognosis, with first line systemic therapy relying primarily on FOLFIRINOX (5FU/irinotecan/oxaliplatin) or AG (Gemcitabine/Nab-Paclitaxel). Therapeutic options for mPC refractory to these regimens remain poorly defined, and data on later-line options are scarce. This prospective, single-arm study evaluated the safety and preliminary efficacy of combining the anti-angiogenic agent surufatinib with the cytotoxic drug TAS-102 (Trifluridine/Tipiracil) in mPC patients who had progressed on ≥ 2 prior lines of therapy.

Methods

mPC patients who were refractory to at least 2 previous regimens were enrolled and received TAS-102 (35 mg/m², po, bid, D1-D5, D8-D12) plus surufatinib (250 mg, po, qd) in a 4-week cycle.

SUBMITTER: Lu Y 

PROVIDER: S-EPMC12492565 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature